Life Science is Our Business Previous Next SOURCING THE GLOBE FOR THE FUTURE OF LIFE SCIENCES Pontifax focuses on groundbreaking innovations in life sciences. We seek transformative healthcare technologies in all development stages. READ MORE ENTREPRENEURSHIP Scouting out disruptive ideas in research centers.Building exceptional companies. EARLY STAGE Providing hands-on guidance, networking and experienceto maximize the […]
Location: Israel
Employees: 11-50
Total raised: $105M
Founded date: 2004
Investors 2
| Date | Name | Website |
| - | Vintage In... | vintage-ip... |
| - | 2B.VC | 2b.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.10.2017 | - | $105M | - |
Mentions in press and media 16
| Date | Title | Description |
| 23.10.2025 | Adcytherix: €105 Million Series A Raised For Advancing Antibody-Drug Conjugate Pipeline And Novel Payload Platform | Adcytherix, a biopharmaceutical company pioneering the design and development of novel antibody-drug conjugates (ADCs), announced the completion of a €105 million (US$122 million) Series A financing round. The funding will accelerate the co... |
| 16.10.2025 | With its notable €105 million raise, French BioTech startup Adcytherix looks to tackle cancer with novel ADC | Marseille-based Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC), has raised €105 million in a Series A financing round to advance its lead candidate and treat high unmet need diseases ... |
| 01.10.2025 | Crystalys Therapeutics: $205 Million Series A Raised For Transforming Gout Treatment | Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for gout, a condition characterized by high levels of uric acid in the blood that can lead to painful arthritis flare-ups. The... |
| 30.09.2025 | Crystalys Therapeutics Raises in $205M Series A Funding | Crystalys Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical company, raised $205M in Series A funding. The round was led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors,... |
| 19.02.2025 | Abcuro: $200 Million (Series C) Raised For Advancing Medicine In Development For Inclusion Body Myositis | Abcuro – a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells – announced the closing of a $200 million Series C financing led by New... |
| 13.02.2025 | Abcuro Raises $200M in Series C Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company, raised $200M in Series C funding. The round was led by New Enterprise Associates (NEA) joined by Foresite Capital with participation from existing investors including RA Capit... |
| 04.04.2023 | Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline | Series A Financing extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR Funds will be used to ensure broad pan-sarcoma development of lead ADC asset uPARAP and to fu... |
| 04.04.2023 | Ysios Capital’s portfolio company Adcendo announces extension of Series A financing to 82M€ to ensure broad development of first-in-class ADC pipeline | 04/04/2023 Nota de prensa YSIOS CAPITAL’S PORTFOLIO COMPANY ADCENDO ANNOUNCES EXTENSION OF SERIES A FINANCING TO 82M€ TO ENSURE BROAD DEVELOPMENT OF FIRST-IN-CLASS ADC PIPELINE Adcendo ApS (“Adcendo”), a biotech company focused on the de... |
| 16.12.2021 | Anaveon raises CHF 110 million | |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies – – Lead program targets Parkinson’s disease and all forms of Gaucher disease – C... |
Show more